Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Study of MM-111, a Bispecific Antibody to ErbB2/3
Date:7/6/2009

Merrimack Pharmaceuticals' second of five oncology pipeline candidates, MM-111, a bispecific antibody, has entered clinical development. Preclinical studies have demonstrated that the bispecific approach shows antitumor activity in a wide range of tumor types. The current Phase 1/2 study will evaluate the human safety and pharmacokinetics (PK) of MM-111. MM-111 is the first bispecific antibody bindng two different receptors on the same cell to enter clinical development.

Cambridge, MA (PRWEB) July 3, 2009 -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1/2 clinical study of the Company's second oncology pipeline candidate, MM-111, a bispecific antibody fusion protein designed to target cancer cells that are characterized by overexpression or amplification of ErbB2 (also known as HER2). MM-111 is the first bispecific antibody binding two different receptors on the same cell to enter clinical development.

"MM-111 is a novel biologic with a unique approach to treating ErbB2 amplification in tumors," said Ulrik B. Nielsen, PhD, Senior Vice President and Chief Scientific Officer at Merrimack. "We used a systems biology approach, integrating computational modeling, experimentation and protein engineering to optimize this therapeutic to address the complex signaling dynamics between ErbB2 and ErbB3 and to exquisitely target cancer cells."

MM-111 has two antibody arms; a targeting arm that binds to ErbB2 with high affinity and a therapeutic arm that binds to ErbB3 (also known as HER3). Both ErbB2 and ErbB3 are members of the ErbB family of receptors, a complex molecular network whose activation is commonly linked with cancer. In 2003, Merrimack researchers identified ErbB3 as a highly sensitive node in the ErbB signaling network and also found it played a dominant role in activation of the PI3 kinase pathway - a pathway believed to be used by cancer cells to sustain survival. The importance of ErbB3 in cancer progression is now widely appreciated. Preclinical data demonstrating the impact of MM-111 in multiple cancer models were presented at the annual meeting of the American Association for Cancer Research in April.

The current Phase 1/2 study will evaluate the human safety and pharmacokinetics (PK) of MM-111. The Phase 1 portion of the study is enrolling patients with tumors that overexpress ErbB2 while the Phase 2 portion of the study will be restricted to ErbB2 overexpressing (HER2+) breast cancer patients. The first dose was administered at South Texas Accelerated Research Therapeutics (START) where enrollment is currently underway. Fox Chase Cancer Center is expected to participate in the trial this July.

"MM-111 has the potential to help patients who are resistant to currently approved ErbB2 therapies," said William J. Slichenmyer, MD, Senior Vice President and Chief Medical Officer at Merrimack. "Preclinical studies of MM-111 have demonstrated that the bispecific approach shows antitumor activity in a wide range of tumor types and we are hopeful this will translate into patient benefit. START and Fox Chase are outstanding cancer research centers and we are excited to be working with leading clinical investigators at both institutions."

Merrimack has developed a broad intellectual property position around its oncology therapeutic portfolio, including its bispecific antibody technology and MM-111. This portfolio includes U.S. and international patent filings relating to compositions of matter and methods of use as well as licensed patents and pending patent applications, trade secrets and proprietary know-how.

About Merrimack
Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for cancer and autoimmune disease. Its first two oncology pipeline candidates, MM-121 and MM-111, are currently in Phase 1 clinical development. The Company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high-throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and well tolerated therapeutics. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. Merrimack is a privately-held company based in Cambridge, Massachusetts.

Contact:
Kathleen Petrozzelli, Corporate Communications, 617-441-1043, kpetrozzelli(at)merrimackpharma.com     http://www.merrimackpharma.com

Betsy Stevenson, RaymondStevenson Healthcare, 860-984-1424, betsy(at)raymondstevenson.com

###

Read the full story at http://www.prweb.com/releases/Merrimack/MM-111/prweb2561474.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Endo Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009
2. Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
3. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases
4. Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
5. Lotus Pharmaceuticals, Inc. Again Awarded GSP Certification
6. Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm
7. Biostar Pharmaceuticals, Inc. Begins Construction of Raw Material Processing Facility of the Herbal Plantation Base
8. Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
9. The Crohns & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners
10. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform
11. DiaGenic to Provide MCI Biomarkers for Merz Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Study of MM-111, a Bispecific Antibody to ErbB2/3
(Date:2/8/2016)... ... February 08, 2016 , ... According to research by ... require dental technicians to be certified or obtain continuing education. To increase patient ... “What’s In Your Mouth?” campaign to inform dentists and patients about the possible ...
(Date:2/7/2016)... Clarkston, Metamora, Michigan (PRWEB) , ... February 07, 2016 , ... ... in recognition of National Wear Red Day. National Wear Red Day is the ... stroke in women. Heart disease and stroke cause 1 in 3 deaths among women ...
(Date:2/7/2016)... Scottsdale, AZ (PRWEB) , ... February 07, 2016 ... ... & Neck and Facial Plastics, has added Kybella® to his medical and surgical ... is a newly approved FDA injectable medication used as a non-surgical alternative for ...
(Date:2/6/2016)... ... February 06, 2016 , ... US Sports Camps is proud to ... This event brings together top non-profit leaders, ultimate organizations, and coaches from around the ... Iani, Bay Area Disc Program Director of Youth and Education, describes this year YUCC ...
(Date:2/6/2016)... ... February 06, 2016 , ... Shark Finds and Kevin ... of a new DRTV campaign with Belly Bands. , Having a dog is great—except ... to puppy pads and find nothing works, get Belly Bands, the easiest way ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... part of a major growth and expansion initiative, Dune Medical ... Chmura as President of Dune Inc., its U.S. division. ... experience in the medical device space will play a large ... --> --> In her new ... and operational functions in the U.S. She is tasked with ...
(Date:2/8/2016)... Mich. , Feb. 8, 2016  The University ... announced today that, as part of the ... one of the first hospitals in the U.S. to ... Karin Muraszko , M.D., U-M,s chair of neurosurgery. ... of neurosurgery. --> The BrightMatter technology ...
(Date:2/8/2016)...  Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) today announced ... December 31, 2015, the Company achieved revenue of $8,195,839, a ... quarter in fiscal 2015. --> ... year 2016 was $2,068,635, or $.03 per share, up 265% ... in the Q2 of fiscal year 2015. Gross margin for ...
Breaking Medicine Technology: